

# ZnO nanoparticles enhanced antibacterial activity of ciprofloxacin against *Staphylococcus aureus* and *Escherichia coli*

Maryam Banoee,<sup>1</sup> Sepideh Seif,<sup>1</sup> Zeinab E. Nazari,<sup>2</sup> Parisa Jafari-Fesharaki,<sup>2</sup> Hamid R. Shahverdi,<sup>3</sup> Ali Moballeggh,<sup>3</sup> Kamyar M. Moghaddam,<sup>1</sup> Ahmad R. Shahverdi<sup>1</sup>

<sup>1</sup>Department of Pharmaceutical Biotechnology and Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

<sup>2</sup>Biotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

<sup>3</sup>Department of Materials Engineering, Faculty of Engineering, Tarbiat Modares University, Tehran, Iran

Received 12 January 2009; revised 15 December 2009; accepted 16 December 2009

Published online 11 March 2010 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/jbm.b.31615

**Abstract:** Nanoparticle metal oxides offer a wide variety of potential applications in medicine due to the unprecedented advances in nanobiotechnology research. In this work, the effect of zinc oxide (ZnO) nanoparticles prepared by mechano-chemical method on the antibacterial activity of different antibiotics was evaluated using disk diffusion method against *Staphylococcus aureus* and *Escherichia coli*. The average size of ZnO nanoparticles was between 20 nm and 45 nm. Although ZnO nanoparticles (500 µg/disk) decreased the antibacterial activity of amoxicillin, penicillin G, and nitrofurantoin in *S. aureus*, the antibacterial activity of ciprofloxacin increased in the presence of ZnO nanoparticles in both test strains. A total of 27% and 22% increase in inhibition zone

areas was observed for ciprofloxacin in the presence of ZnO nanoparticles in *S. aureus* and *E. coli*, respectively. The enhancing effect of this nanomaterial on the antibacterial activity of ciprofloxacin was further investigated at three different contents (500, 1000, and 2000 µg/disk) against various clinical isolates of *S. aureus* and *E. coli*. The enhancing effect of ZnO nanoparticles on the antibacterial activity of ciprofloxacin was concentration-dependent against all test strains. The most enhancing activities were observed in the contents of the 2000 µg/disk. © 2010 Wiley Periodicals, Inc. *J Biomed Mater Res Part B: Appl Biomater* 93B: 557–561, 2010.

**Key Words:** bioactive material, nanomedicine, nanotechnology

## INTRODUCTION

Despite prodigious efforts, bacterial resistance is still considered as a major drawback in chemotherapy of many infection diseases.<sup>1</sup> Recently, however, certain natural products and synthetic compounds have successfully shown to increase antibacterial activity of antibiotics against different clinically isolated resistant test strains.<sup>2–11</sup> Moreover, there are extensive reports on antibacterial effects of silver<sup>12–15</sup> and copper nanoparticles.<sup>16</sup> Also the combination of silver nanoparticles with antibiotics was investigated in our previous work, where we demonstrated that antibacterial activity of penicillin G, amoxicillin, erythromycin, clindamycin, and vancomycin against *Staphylococcus aureus* and *Escherichia coli* significantly increases in the presence of silver nanoparticles.<sup>17</sup> However, the effect of other nanomaterial such as zinc oxide (ZnO) nanoparticles in combination with antibiotics has not been yet investigated. ZnO is widely used as food additive, food supplement, and pharmaceutical ingredient.<sup>18–21</sup> Among other metal oxide nanomaterials, ZnO nanoparticles are famous for their catalytic efficiency, chemical stability, and strong adsorption ability.<sup>22</sup>

In this study, for the first time, the antibacterial activity of different antibiotics was evaluated against different clinical strains of *S. aureus* and *E. coli* either in presence and absence of sub-inhibitory concentrations of ZnO nanoparticles, using

disk diffusion assay. ZnO nanoparticles showed considerable enhancing effects on the antibacterial activity of ciprofloxacin against different clinical strains of *S. aureus* and *E. coli*.

## MATERIALS AND METHODS

### Synthesis of ZnO nanoparticles

ZnO nanoparticles were freshly prepared by a recently described mechanochemical method using anhydrous ZnCl<sub>2</sub>, anhydrous Na<sub>2</sub>CO<sub>3</sub>, and NaCl as starting materials.<sup>23</sup> NaCl was used as dilutive additive to the starting powder. The stoichiometric mixture of the starting powders was milled according to the reaction below:




The diameter of balls and their w/w ratio to powder mass were 10 mm and 10:1, respectively. Mechanochemical milling process was then carried out with planetary mill for 9 h at 250 rpm. Powder was calcined in air at 300°C for 30 min.<sup>23</sup>



Finally, ZnO nanoparticles were obtained when calcinated sample powders were washed with distilled water for thrice and dried. A colloidal stock solution of ZnO nanoparticles in ethanol (10 mg/mL) was prepared. This colloidal

**Correspondence to:** A. R. Shahverdi; e-mail: shahverd@sina.tums.ac.ir

Contract grant sponsor: Deputy of Research, Tehran University of Medical Sciences, Tehran, Iran



**FIGURE 1.** Transmission electron micrographs of prepared zinc oxide nanoparticles using a mechanochemical method.

stock solution was sonicated (ultrasound Elma T 780/H) for 15 min and used for further biological experiments and sample characterization by transmission electron microscopy (Philips CM200).

#### Disk diffusion assay

The disk diffusion susceptibility test was carried out on Müeller-Hinton agar (Difco, Germany) plates in order to examine the antibacterial activity of candidate antibiotics against test strains. Standard antibiotics disks listed in Table I were purchased from Mast Co., UK. To determine the combined effects, each standard paper disk was further impregnated with ZnO nanoparticles at a sub-inhibitory amount of 500 µg/disk. A single colony of test strains was grown overnight in Müeller-Hinton liquid medium (Difco) on a rotary shaker (200 rpm) at 35°C. The inocula were prepared by diluting the overnight cultures with 0.9% NaCl to a 0.5 McFarland standard and applied to the plates along with standard and test disks containing ZnO nanoparticles. Different clinical test strains of *S. aureus* and *E. coli* were isolated at Ghods Polyclinic Laboratory (Tehran, Iran) and used as test strains throughout this investigation. The confirmation of all bacterial isolates was carried out by conventional microbiological identification methods.<sup>24</sup> ZnO nanoparticles at the content of 500 µg/disk was tested as control. After incubation at 35°C for 18 h, the inhibition zones were measured. Mean surface area of the inhibition zone (mm<sup>2</sup>) was calculated from mean diameter of each tested antibiotic. The percent of increase in the inhibition zone areas for different antibiotics against *S. aureus* were calculated as  $(b^2 - a^2)/a^2 \times 100$ , where *a* and *b* are the inhibition zones for A and B, respectively. In the same way,  $(d^2 - c^2)/c^2$  was used for antibiotics against *E. coli*. All experiments were performed in triplicate.

#### RESULTS


Figure 1 shows representative transmission electron micrograph images recorded from the ZnO nanoparticle drop-coated film that was synthesized by mechano-chemical

method. According to transmission electron micrograph data, particles vary in size from 20 to 45 nm. The combination effect of ZnO nanoparticles (500 µg) with different antibiotics was primarily investigated against two clinical isolates of *S. aureus* and *E. coli* by the disk diffusion method (Fig. 2). The diameters of inhibition zones (mm) in antibiotic disks either in presence or lack of ZnO nanoparticles are outlined in Table I. Although the ZnO nanoparticles decreased the antibacterial activity of amoxicillin, penicillin G, and nitrofurantoin against *S. aureus*, the antibacterial activity of ciprofloxacin increased in the presence of ZnO nanoparticles against both test strains. In detail, the surface areas of inhibition zones of ciprofloxacin in both *S. aureus* and *E. coli* plates increased in presence of ZnO nanoparticles by 27% and 22%, respectively. No enhancing effect on the antibacterial activity other antibiotics was observed against mentioned test strains at the concentration tested (500 µg/disk).

In the second round of the test—in order to investigate the effect of ZnO nanoparticles on antibacterial activity of ciprofloxacin—the experiment was repeated; this time with 5 µg/disk concentration of ciprofloxacin supplemented either with or without three sub-inhibitory levels of ZnO nanoparticles (500, 1000, and 2000 µg/disk), using four clinical isolates of *S. aureus* and three clinical isolates of *E. coli*. (Table II). As clear from the Table II, ZnO nanoparticles improved the antibacterial activity of ciprofloxacin in a concentration-dependent manner. This pattern was true for all clinical isolates and the most enhancing activity was observed in concentration of 2000 µg/disk. ZnO nanoparticles caused 39% to 63% increase in inhibition zone areas of ciprofloxacin in different isolates of *S. aureus*. However, for *E. coli* isolates, the increase in inhibition zones varied from 17% up to the considerable amount of 93% in presence of ZnO nanomaterials.

#### DISCUSSION

In this study, the antibacterial activity of ZnO nanoparticles alone was tested at the concentrations of 500, 1000, and



**FIGURE 2.** Agar disk diffusion assay testing the effect of ciprofloxacin against *Escherichia coli* (A) and *Staphylococcus aureus* (B) both in presence and absence of zinc oxide (ZnO) nanoparticles (500 µg/disk). Test strains were spread onto Müller-Hinton Agar plates. A ciprofloxacin standard disk was further loaded with ZnO nanoparticles (500 µg/disk) (Cip + ZnO) and placed onto the left side of the inoculated agar plates. Ciprofloxacin standard disks (Cip) and ZnO nanoparticles containing disks (500 µg/disk) were also applied as controls. In both test strains, inhibition zones around ZnO nanoparticle containing ciprofloxacin disks were broader than nanoparticle-free disks.

2000 µg/disk. The ZnO nanoparticle levels of 500, 1000, and 2000 µg/disks were chosen to guarantee that the effect produced was due to the combination effect of ZnO nanoparticle-ciprofloxacin and not to the effect of the ZnO nanoparticles themselves.

Candidate antibiotics were carefully chosen because they represent major classes of antibiotics (penicillins, cephalosporins, macrolides, aminoglycosides, tetracyclines, fluoroquinolones, lincomycin derivatives, nitrofurans, and glycopeptides). However, different antibiotics showed different activities in presence of ZnO nanoparticles. In detail, antibacterial activity of amoxicillin, penicillin G, and nitrofurantoin against *S. aureus* decreased, whereas that of ciprofloxacin

increased in both test strains. The remaining antibiotics were almost indifferent to the presence of ZnO nanoparticles.

An explanation for the increased activity in the presence of ZnO nanoparticles in *S. aureus* would be based on the assumption that ZnO nanoparticles may interfere with the pumping activity of NorA protein of *S. aureus*. The NorA protein mediates the active efflux of hydrophilic fluoroquinolones from the cell, conferring resistance upon the organism.<sup>25–28</sup> Because recent reports suggest that nano-sized metal oxides such as zinc oxide and titanium dioxide possess the ability to induce faster electron transfer kinetics in the active site of the enzymes,<sup>29,30</sup> it seems likely that ZnO

**TABLE I.** Inhibition Zones (mm<sup>2</sup>) of Candidate Antibiotics Against *Staphylococcus aureus* and *Escherichia coli* (Either in Presence or Absence of ZnO Nanoparticles at Content of 500 µg/disk)<sup>a</sup>

Antibiotics (µg/disk)	<i>Staphylococcus aureus</i>			<i>Escherichia coli</i>		
	Antibiotic only (A)	Antibiotic plus ZnO Nanoparticles (B)	Increase/Decrease in Area (%) <sup>b</sup>	Antibiotic only (C)	Antibiotic Plus ZnO Nanoparticles (D)	Increase in Area (%) <sup>b</sup>
Penicillin G 10	18.5 ± 0.5	17 ± 0.0	−15.0	–	–	–
Amoxicillin 10	15 ± 1.0	12 ± 0.5	−36.0	–	–	–
Carbenicillin 100	25 ± 0.5	24 ± 0.5	−7.80	–	–	–
Cephalexin 30	–	–	–	15 ± 0.5	15 ± 0.5	0.0
Cefixime 5	–	–	–	13 ± 1.0	13 ± 0.5	0.0
Erythromycin 5	–	–	–	15 ± 1.0	14 ± 0.0	−12.9
Gentamicin 10	8 ± 0.5	8 ± 0.5	–	–	–	–
Amikacin 30	–	–	–	15 ± 0.5	15 ± 0.5	0.0
Tetracycline 30	12 ± 0.5	12 ± 0.5	0.0	11 ± 0.0	11 ± 0.5	0.0
Ciprofloxacin 5	20 ± 0.5	22.5 ± 1.0	27.0	19 ± 0.0	21 ± 1.0	22.0
Clindamycin 2	12 ± 1.0	12 ± 1.0	0.0	17 ± 0.5	17 ± 0.5	0
Nitrofurantoin 300	27 ± 1.0	25 ± 0.5	−14.0	17 ± 0.5	17 ± 0.5	0
Nalidixic acid 30	–	–	–	–	–	–
Vancomycin 30	19 ± 0.5	18 ± 1.0	−10.0	14 ± 0.5	13 ± 0.5	−0.13776

ZnO, zinc oxide.

<sup>a</sup> All experiments were done in triplicate.

<sup>b</sup> Mean surface area of the inhibition zone (mm<sup>2</sup>) was calculated from the mean diameter of each tested antibiotic. The percent of increase in the inhibition zone areas for different antibiotics against *S. aureus* were calculated as  $(b^2 - a^2)/a^2 \times 100$ , where  $a$  and  $b$  are the inhibition zones for A and B, respectively. In the same way,  $(d^2 - c^2)/c^2$  was used for antibiotics against *E. coli*.

**TABLE II. The Combination Effect of ZnO Nanoparticles in Three Different Contents (500, 1000, and 2000 µg/disk) with Ciprofloxacin Against Seven Clinical Isolates of *Staphylococcus aureus* and *Escherichia coli*<sup>a</sup>**

Isolates	Zone of inhibition (mm)						
	Antibiotic only (A)	Antibiotic Plus ZnO Nanoparticles (B)			Increase in Area (%) <sup>b</sup>		
		500 µg	1000 µg	2000 µg	500 µg	1000 µg	2000 µg
<i>S. aureus</i> (isolate 1)	21 ± 0.5	22.5 ± 0.5	24 ± 1.0	26.5 ± 0.5	15	30	59
<i>S. aureus</i> (isolate 2)	18 ± 0.5	20 ± 1.0	22.5 ± 0.0	24.5 ± 0.5	23	56	85
<i>S. aureus</i> (isolate 3)	14 ± 0.0	15.5 ± 0.5	17.5 ± 1.0	20 ± 0.0	23	56	104
<i>S. aureus</i> (isolate 4)	27 ± 1	28 ± 0.5	30.5 ± 1.0	32 ± 1.0	8	27	40
<i>E. coli</i> (isolate 1)	9 ± 0.5	10 ± 0.5	11 ± 1.0	12.5 ± 1.0	23	49	93
<i>E. coli</i> (isolate 2)	40 ± 1	41.5 ± 0.5	43 ± 1.0	45 ± 1.5	7.6	16	27
<i>E. coli</i> (isolate 3)	36 ± 0.0	36 ± 0.5	37.5 ± 0.5	39 ± 0.5	0	8	17

ZnO, zinc oxide.

<sup>a</sup> All experiments were done in triplicate.

<sup>b</sup> Mean surface area of the inhibition zone (mm<sup>2</sup>) was calculated for each tested antibiotic from the mean diameter. The percent of increases of inhibition zone area for different antibiotics against *S. aureus* were calculated as  $(b^2 - a^2)/a^2 \times 100$ , where *a* and *b* are the inhibition zones for A and B, respectively. In the same way,  $(d^2 - c^2)/c^2$  was used for antibiotics against *E. coli*.

nanoparticles may interfere with the pumping activity of the this protein. Efflux transporters were identified in other bacteria<sup>31</sup> and ZnO nanoparticles may interfere with these efflux pump systems as well. Another explanation would be that ZnO nanoparticles may enhance the absorption of antibiotics into *S. aureus* cells, which is mainly mediated by membrane Omf protein,<sup>32</sup> thereby improving their performances. Omf protein is considered to be responsible for the permeation of quinolones to the cell membrane.<sup>33–35</sup>

Ciprofloxacin is a well-known member of Fluoroquinolones. The mechanism of action of quinolone agents is based on their ability to penetrate into bacterial cells and to inhibit DNA gyrase,<sup>36,37</sup> an enzyme which is responsible for superhelical twists in bacterial DNA.<sup>38</sup> Therefore, considering the nitrogen atoms of quinolone ring in ciprofloxacin, and the hydroxylated surface<sup>39</sup> of ZnO nanoparticles, it is possible that ciprofloxacin–ZnO nanoparticle system may be stabilized through a network of ionic interactions between protonated nitrogen atoms of quinolone and hydroxylated surface of ZnO nanoparticles.

The interactions of complex-forming metal ions such as Co (II), Ni (II), and Cu (II) with ciprofloxacin is previously characterized by Spectroscopy and X-ray analysis, which reveals that ciprofloxacin is capable of forming complexes with metal ions.<sup>40,41</sup> In this context, it is probable that the electron-donor fluore atom in ciprofloxacin may interact with the chelating Zn atom, thereby stabilizing the ciprofloxacin–ZnO nanoparticle combination. This explanation is in good agreement with the study of Patel et al., which showed the improved interaction of ciprofloxacin with DNA in the presence of the chelating cobalt II elements and the ability of ciprofloxacin to form complexes with chelating agents.<sup>42</sup> Another explanation relies on the presence of the carboxyl group in ciprofloxacin as an obvious target for chelation by metal ions, as recognized in previous studies.<sup>43</sup> The chelation of ring carbonyl group oxygen atom by Mg<sup>2+</sup> metal ion is demonstrated earlier.<sup>44</sup> It seems likely that the carbonyl group and the carboxylic oxygen's may form complexes with Zn atom to increase the stability of ciprofloxacin–ZnO nanoparticles.

These unique features of ciprofloxacin (three amino groups together with the electron-donor fluore group) may have enabled it to form a fairly strong interaction with ZnO nanoparticles. In this context, the antibacterial activity of other antibiotics tested, either decreased or remained the same, perhaps due to the probability that they form weak hydrogen bonds with hydroxylated ZnO nanoparticles or lack sufficient targets to form complexes with Zn atom. More studies remain to be done, to describe in detail, the mechanism underlying the enhanced activity of ciprofloxacin in combination with ZnO nanoparticles.

## CONCLUSIONS

Many efforts have been made to overcome the emerging problem of antibiotic resistance among a variety of disease causing bacteria and advances in the field of nanobiotechnology may offer a great opportunity of research in this field. Therefore, studies on combination of antibiotic agents and synthetic and natural organic or inorganic nanomaterials are of great importance. The potential advantages of using organic or inorganic nanoparticles as drug carriers are well reviewed in the literature.<sup>45–47</sup> Here, for the first time, we report that antibacterial activity of ciprofloxacin against two clinical test strains: *S. aureus* and *E. coli* improves in presence of ZnO nanoparticles. Because of its potential synergistic effect with ciprofloxacin, ZnO nanoparticles may be considered as a valuable adjuvant in combination therapy of ciprofloxacin. However, the antibacterial activity of antibiotics such as amoxicillin against *S. aureus* was decreased considerably in the presence of ZnO nanoparticles; therefore, the combination of ZnO nanoparticles with these antibiotics cannot be recommended for possible combination therapy.

## REFERENCES

- Bennett PM. Plasmid encoded antibiotic resistance: Acquisition and transfer of antibiotic resistance genes in bacteria. *Br J Pharmacol* 2008;153:S347–S357.
- Lak P, Amini M, Safavi M, Shafiee A, Shahverdi AR. Enhancement of the antibacterial activity of ciprofloxacin against *Staphylococcus aureus* by 3-alkyl esters and 3-aryl esters of hexahydroquinoline derivatives. *Arzneimittelforschung* 2008;58:464–268.

3. Shahverdi AR, Monsef-Esfahani HR, Tavasoli F, Zaheri A, Mirjani R. Trans-cinnamaldehyde from *Cinnamomum zeylanicum* bark essential oil reduces the clindamycin resistance of *Clostridium difficile* in vitro. *J Food Sci* 2007;72:S055–S058.
4. Shahverdi AR, Fakhimi A, Zarrini G, Dehghan G, Iranshahi M. Galbanic acid from *Ferula szowitsiana* enhanced the antibacterial activity of penicillin G and cephalixin against *Staphylococcus aureus*. *Biol Pharm Bull* 2007;30:1805–1807.
5. Rafii F, Shahverdi AR. Comparison of essential oils from three plants for enhancement of antimicrobial activity of nitrofurantoin against enterobacteria. *Chemotherapy* 2007;53:21–25.
6. Gibbons S. Plants as a source of bacterial resistance modulators and anti-infective agents. *Phytochem Rev* 2005;4:63–68.
7. Liu LX, Durham DG, Richards RME. Vancomycin resistance reversal in enterococci by flavonoids. *J Pharm Pharmacol* 2001;53:129–132.
8. Renau TE, Hecker SJ, Lee VJ. Antimicrobial potentiation approaches: targets and inhibitors. *Ann Rep Med Chem* 1998;33:121–130.
9. Shin S, Pyun M-S. Anti candida effect of estragole in combination with ketoconazole or amphotericin B. *Phytother Res* 2004;8:827–830.
10. Wright GD. Resisting resistance: New chemical strategies for battling superbugs. *Chem Biol* 2000;7:R127–R132.
11. Wright GD. Bacterial resistance to antibiotics: Enzymatic degradation and modification. *Adv Drug Deliv Rev* 2005;57:1451–1470.
12. Sharma VK, Yngard RA, Lin Y. Silver nanoparticles on *Escherichia coli*. *Adv Colloid Interface Sci* 2009;145:83–96.
13. Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. *Biotech Adv* 2009;27:76–83.
14. Lok C, Ho C, He Q, Yu W, Sun H, Tam PK, Chiu J, Che C. Silver nanoparticles: partial oxidation and antibacterial activities. *J Biol Inorg Chem* 2007;12:527–534.
15. Fabera J. Silver nanoparticle impact on bacterial growth: Effect of pH, concentration, and organic matter. *J Environ Sci Technol* 2009;43:7285–7290.
16. Ren G. Characterization of copper oxide nanoparticles for antimicrobial applications. *J Antimicrob Agents* 2009;33:587–590.
17. Shahverdi AR, Fakhimi A, Shahverdi HR, Minaian S. Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against *Staphylococcus aureus* and *Escherichia coli*. *Nanomedicine* 2007;3:168–171.
18. Söderberg TA. Effects of zinc oxide, rosin and resin acids and their combinations on bacterial growth and inflammatory cells. *Scand J Plast Reconstr Surg Hand Surg Suppl* 1990;22:1–87.
19. Lansdown A, Mirastschijski U, Stubbs N, Scanlon E, Ågren M. Zinc in wound healing: Theoretical, experimental, and clinical aspects. *Wound Repair Regen* 2007;15:2–16.
20. Sandstead HH. Understanding zinc: Recent observations and interpretations. *J Lab Clin Med* 1994;124:322–327.
21. Fabris N, Mocchegiani E. Zinc, human diseases and aging. *Aging (Milano)* 1995;7:77–93.
22. Singh SP, Arya SK, Pandey P, Saha S, Streenivas K, Malhorta BD, Gupta V. Cholesterol biosensors based on rf sputtered zinc oxide nanoporous thin film. *Appl Phys Lett* 2007;91:063901 (3 pages).
23. Moballeghe A, Shahverdi HR, Aghababazadeh R, Mirhabibi AR. ZnO nanoparticles obtained by mechanochemical technique and the optical properties. *Surface Sci* 2007;601:2850–2854.
24. Isenberg HD. *Clinical Microbiology Procedures Handbook*. Washington D.C.: ASM Press; 1992.
25. Huet AA, Rayagada JL, Mendiratta K, Seo SM, Kaatz GW. Multidrug efflux pump overexpression in *Staphylococcus aureus* after single and multiple in vitro exposure to biocides and dyes. *Microbiology* 2008;154:3144–3153.
26. Yu J, Grinius L, Hooper DC. NorA functions as a multidrug efflux protein in both cytoplasmic membrane vesicles and reconstituted proteoliposomes. *J Bacteriol* 2002;184:1370–1377.
27. Kaatz GW, Seo SM. Inducible NorA-mediated multidrug resistance in *Staphylococcus aureus*. *Antimicrob Agents Chemother* 1995;39:2650–2655.
28. Neyfakh AA, Borsch CM, Kaatz GW. Fluoroquinolone resistance protein NorA of *Staphylococcus aureus* is a multidrug efflux transporter. *Antimicrob Agents Chemother* 1993;37:128–129.
29. Kumor SA, Chen S. Nanostructured zinc oxide particles in chemically modified electrodes for biosensor applications. *Anal Lett* 2008;41:141–158.
30. Huang JY, Liu YX, Gan X, Liu XJ. A nitric oxide biosensor based on the photovoltaic effect of nano titanium dioxide on hemoglobin. *J Anal Chem* 2009;64:735–737.
31. Ryan BM, Dougherty TJ, Beaulieu D, Chuang J, Dougherty BA, Barrett JF. Efflux in bacteria: What do we really know about it? *Expert Opin Investig Drugs* 2001;10:1409–1422.
32. Fernandes F, Neves P, Gameiro P, Loura LMS, Prieto M. Cyprofloracin interaction with bacterial protein *OmpF*: Modeling of FRET from a multi-tryptophan protein trimer. *Biochim Biophys Acta* 2007;1768:2822–2830.
33. Chevalier J, Mallea M, Pages JM. Comparative aspects of the diffusion of norfloxacin, cefepime and spermine through the F porin channel of *Enterobacter cloacae*. *Biochem J* 2000;348:223–227.
34. Piddock LJV, Jin YF, Ricci V, Asuquo AE. Quinolone accumulation by *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Escherichia coli*. *J Antimicrob Chemother* 1999;43:61–70.
35. Mascaretti OA. *Bacterial Versus Antibacterial Agents: An Integrated Approach*. Washington D. C.: ASM Press; 2003.
36. Pestova E, Millichap JJ, Noskin GA, Peterson LR. Intracellular targets of moxifloxacin: A comparison with other fluoroquinolones. *J Antimicrob Chemother* 2000;45:583–590.
37. Turel I, Leban I, Bukovec N. Crystal structure and characterization of the bismuth (III) compound with quinolone family member (ciprofloxacin). *Antibacterial study. J Inorg Biochem* 1997;66:241–245.
38. Yoshida H, Nakamura M, Bogaki M, Ito H, Kojima T, Hattori H, Nakamura S. Mechanism of action of quinolones against *Escherichia coli* DNA gyrase. *Antimicrob Agents Chemother* 1993;37:839–845.
39. Noei H, Qiu H, Wang Y, Loffler E, Woll C, Muhler M. The identification of ZnO nanoparticles by infrared spectroscopy. *Phys Chem Chem Phys* 2008;10:7092–7097.
40. López-Gresa MP, Ortiz R, Perelló L, Latorre J, Liu-González M, García-Granda S, Pérez-Priede M, Cantón E. Interactions of metal ions with two quinolone antimicrobial agents (cinoxacin and ciprofloxacin). Spectroscopic and X-ray structural characterization. *Antibacterial studies. J Inorg Biochem* 2002;92:65–74.
41. Wallis SC, Gahan LR, Charles BG, Hambley TW, Duc-kworth PA. Copper (II) complexes of the fluoroquinolone antimicrobial ciprofloxacin synthesis, X-ray structural characterization, and potentiometric study. *J Inorg Biochem* 1996;62:1–16.
42. Patel MN, Chhasatia MR, Gandhi DS. DNA-interaction and in vitro antimicrobial studies of some mixed-ligand complexes of cobalt (II) with fluoroquinolone antibacterial agent ciprofloxacin and some neutral bidentate ligands. *Bioorg Med Chem Lett* 2009;19:2870–2873.
43. Morais Cabral JH, Jackson AP, Smith CV, Shikotra N, Maxwell A, Liddington RC. Crystal structure of the breakage-reunion domain of DNA gyrase. *Nature* 1997;388:903–906.
44. Skauge T, Turel I, Sletten E. Interaction between ciprofloxacin and DNA mediated by Mg<sup>2+</sup> ions. *Inorg Chim Acta* 2002;339:239–247.
45. Cho K, Wang X, Nie S, Chen Z, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. *Clin Cancer Res* 2008;14:1310–1316.
46. Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. *Am J Respir Crit Care Med* 2005;172:1487–1490.
47. Jurgons R, Seliger C, Hilpert A, Trahms L, Odenbach S, Alexiou C. Drug loaded magnetic nanoparticles for cancer therapy. *J Phys Condens Matter* 2006;18:2893–2902.